Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia.

Trial Profile

Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2013

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Niacin (Primary)
  • Indications Hyperlipidaemia; Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type IIb
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 09 Sep 2009 Planned number of patients changed from 990 to 1220 as reported by ClinicalTrials.gov.
    • 14 Jun 2009 Results were presented at the 15th International Symposium on Atherosclerosis (ISA) in Boston, MA.
    • 30 Aug 2008 24-week interim results presented at the 2008 Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top